Gene engineering bacterium for efficiently converting Echinocandin B and preparation method thereof

A technology of genetically engineered bacteria and echinocandin, which is applied in the field of genetically engineered bacteria that can efficiently transform echinocandin B and its preparation, can solve the problem of low efficiency of transforming echinocandin B and long growth cycle of actinomycetes. and other issues to achieve the effect of stable conversion efficiency

CN102443561AInactive Publication Date: 2012-05-09SHANGHAI INST OF PHARMA IND
4 Cites 3 Cited by

Patent Information

Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Publication Date
2012-05-09
Estimated Expiration
Not applicable · inactive patent

Smart Images

  • Figure 1
    Figure 1
  • Figure 2
    Figure 2
  • Figure 3
    Figure 3
Patent Text Reader

Abstract

The invention discloses a gene engineering bacterium for efficiently converting Echinocandin B and a preparation method thereof. The gene engineering bacterium is the engineering bacterium with an expression cassette of Echinocandin B acylase removal genes integrated in a genome of a wild strain of Streptomyces lividans. Through the conversion verification of the Echinocandin B, compared with that of the wild strain of Actinoplanes utahensis, the conversion speed of the gene engineering bacterium is improved by 1.5 times.
Need to check novelty before this filing date? Find Prior Art

Description

technical field

[0001] The invention belongs to the field of bioengineering, in particular to a genetic engineering bacterium for efficiently transforming echinocandin B and a preparation method thereof. Background technique

[0002] In the past two decades, fungal infections that seriously endanger human life and health have been increasing in both frequency and type of infection, especially in immunosuppressed patients. In the nearly 30 years before the mid-1980s, amphotericin has been the main drug to control clinical fungal infections. Although its neurotoxicity is relatively high, there is no clinical choice. Until the successful development of imidazole and triazole antifungal drugs in the late 1980s and 1990s, fungal infections could be effectively and safely controlled clinically. However, with the use of these antifungal drugs, drug-resistant bacteria continue to emerge, so it is particularly important to find a new safe and effective antifungal drug.

[0003] Ech...

Examples

Embodiment 1

[0032] Example 1 Cloning of erythromycin resistance gene promoter and echinocandin B deacylase gene coding sequence

[0033] First, the total genome of the erythromycin-producing strain S.erythraea HL 3168E3 (ie S.erythraea ATCC11635) was used as a template to clone the erythromycin resistance gene promoter, the upstream primer: 5'-AAAAGATCTTCTAGAAGCCCGACCCGAGCA-3'; the downstream primer: 5' -AAAGAATTCTCCGGAGGTCGCACC-3', PCR was performed, and the resulting PCR product was purified and connected to plasmid pSP72 (purchased from Takara Company) to obtain plasmid pYG-LAJ-3, and sequenced, the sequence was compared with the online sequence (Gene ID: 4940594) Origin is 100%. The plasmid pYG-LAJ-3 was directly digested to obtain the erythromycin resistance gene promoter (EcoR I / Bgl II).

[0034] Primers were designed according to the echinocandin B deacylase gene and its sequence (Gene ID: 33036681) in GenBank, upstream: 5'-AAAAGATCTTCTAGAAGCCCGACCCGAGCA-3'; downstream: 5'-AAAGAAT...

Embodiment 2

[0036] Example 2 Construction of specific site integration plasmid, conjugative transfer

[0037] The erythromycin resistance gene promoter obtained in Example 1 and the fragment (XbaI / XbaI) of the echinocandin B deacylase gene coding sequence were connected into the plasmid pSET152 (XbaI / XbaI, dephosphorylated) purchased from Takara Company ) to obtain plasmid pYG-LAJ-6. This recombinant plasmid is an integrated plasmid containing the erythromycin resistance gene promoter and the echinocandin B deacylase gene coding sequence. This recombinant plasmid is used to transform Escherichia coli DH5α, and the transformants are picked and cultured in LB. The plasmid was digested and verified by PCR, and the site-specific integration plasmid pYG-LAJ-6 was finally constructed. The schematic diagram of the above plasmid construction process is shown in figure 1 .

[0038] Streptomyces lividans TK24 (CPCC 260835, derived from the Medicinal Microorganism Collection Center of China Commi...

Embodiment 3

[0039] Example 3 Screening of Specific Site Homologous Recombination Engineering Bacteria

[0040] The zygotes were picked and cultured in TSB containing abramycin (50 μg / ml), and then the bacterial solution was applied to a slant medium containing abramycin (50 μg / ml) (soluble starch 2.0%, NaCl 0.05%) , K 2 HPO 4 ·3H 2 O 0.05%, KNO 3 0.1%, MgSO 4 ·7H 2 O 0.05%, FeSO 4 ·7H 2 O 0.001%, purified agar powder 2.0%, pH 7.4), cultivated at 30°C. Because pSET152 contains phage The integration site (attP), which can be specifically homologously integrated with the attB site in the genome of Streptomyces lividans, integrates the abramycin resistance gene and erythromycin resistance gene carried by the plasmid pYG-LAJ-6 The promoter and echinocandin B deacylase gene were inserted into the attB site in the chromosome of Streptomyces lividans, and amplified synchronously with chromosome replication, and the zygote could stably express the abramycin resistance gene and Echinocan...